Fly News Breaks for January 10, 2020
Jan 10, 2020 | 06:41 EDT
Oppenheimer analyst Jay Olson downgraded Portola Pharmaceuticals to Perform from Outperform with a price target of $17, down from $40. The company announced Q4 Andexxa revenues below expectations with commentary describing certain headwinds, Olson tells investors in a research note. The Q4 addition of 90 new hospitals ordering Andexxa fell well below the analyst's 125 estimate. He reduced his estimates to reflect the Andexxa headwinds and downgraded Portola.
News For PTLA From the Last 2 Days
There are no results for your query PTLA